Filing Flows

Filing Flows › Companies › Korsana Biosciences › Cash flow

Korsana Biosciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$47.1M in Q3 2026 · −$41.0M over twelve months

Operating cash flow−$46.8M
Capital spending−$231K
Free cash flow−$47.1M

Analysis

In Q3 2026, Korsana Biosciences generated −$46.8M of operating cash flow and spent $231K on capital projects, leaving free cash flow of −$47.1M. That is $36.7M less than in Q3 2025 (−$10.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$41.0M; the largest uses were operating cash flow ($41.0M); besides operations, cash came from other financing ($190M); the cash balance rose by $148M.

Operating cash flow was −$46.8M against net income of −$46.4M. The largest differences: stock-based pay +$17.3M, payables +$343K.

Free cash flow

Korsana Biosciences: free cash flow by quarterKorsana Biosciences: free cash flow by quarter$360KQ4 2024−$968KQ1 2025−$503KQ2 2025−$10.3MQ3 2025$8.5MQ4 2025−$1.2MQ1 2026−$1.4MQ2 2026−$47.1MQ3 2026
Operating cash flow less capital spending.
Korsana Biosciences: operating cash flow against capital spendingKorsana Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending$360K$0Q4 2024−$968K$0Q1 2025−$503K$0Q2 2025−$10.3M$0Q3 2025$8.5M$0Q4 2025−$1.2M$66KQ1 2026−$1.4M$0Q2 2026−$46.8M$231KQ3 2026
Latest (Q3 2026): Operating cash flow −$46.8M, Capital spending $231K.

Capital allocation, year by year

Korsana Biosciences: where the cash came from (up) and went (down), by fiscal yearKorsana Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$36.5MFY2021: Shares issued $282KFY2021: Asset sales $1.5MFY2021: Capital spending −$7K$1.7MFY2021FY2022: Operating cash flow −$40.6MFY2022: Shares issued $29K$29KFY2022FY2023: Operating cash flow −$21.2MFY2023: Shares issued $8.1MFY2023: Asset sales $10.4M$18.5MFY2023FY2024: Operating cash flow −$4.3MFY2024FY2025: Operating cash flow −$3.3MFY2025: Shares issued $1.4M$1.4MFY2025
Over these 5 years operating cash flow totalled −$106M; the largest uses were operating cash flow ($106M) and capital spending ($7K). Cash-flow statements as filed.

Where the cash came from and went

Korsana Biosciences: sources (+) and uses (−) of cash, Q3 2026Korsana Biosciences: sources (+) and uses (−) of cash, Q3 2026Other financing$351MCash drawn (+) / kept (−)−$304MOperating cash flow−$46.8MCapital spending−$231K
Korsana Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Korsana Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$190MCash drawn (+) / kept (−)−$148MOperating cash flow−$41.0MNot reconciled−$297K

From profit to cash

Korsana Biosciences: net income to operating cash flow, Q3 2026Korsana Biosciences: net income to operating cash flow, Q3 2026Net income−$46.4MStock-based pay$17.3MPayables$343KOperating cash flow−$46.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$46.8M−$231K—−$304M−$47.1M
Q2 2026−$1.4M——$1.4M−$1.4M
Q1 2026−$1.2M−$66K—$417K−$1.2M
Q4 2025$8.5M——$154M$8.5M
Q3 2025−$10.3M——−$154M−$10.3M
Q2 2025−$503K——$633K−$503K
Q1 2025−$968K—$1.4M−$407K−$968K
Q4 2024$360K——−$360K$360K

Korsana Biosciences: income statement and cash flow

Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%. The chart follows the revenue to costs, profit and cash.

Korsana Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.